MX2021002666A - Proceso para la preparacion de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-( 3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]a nulen-2-carboxilato de metilo. - Google Patents

Proceso para la preparacion de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-( 3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]a nulen-2-carboxilato de metilo.

Info

Publication number
MX2021002666A
MX2021002666A MX2021002666A MX2021002666A MX2021002666A MX 2021002666 A MX2021002666 A MX 2021002666A MX 2021002666 A MX2021002666 A MX 2021002666A MX 2021002666 A MX2021002666 A MX 2021002666A MX 2021002666 A MX2021002666 A MX 2021002666A
Authority
MX
Mexico
Prior art keywords
annulene
benzo
carboxylate
methyl
oxyphenyl
Prior art date
Application number
MX2021002666A
Other languages
English (en)
Spanish (es)
Inventor
Christian Wehrey
Michel Tabart
Alain Rabion
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2021002666A publication Critical patent/MX2021002666A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/1616Coordination complexes, e.g. organometallic complexes, immobilised on an inorganic support, e.g. ship-in-a-bottle type catalysts
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02Dicarboxylic acids
    • C07C55/06Oxalic acid
    • C07C55/07Salts thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255Tartaric acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Health & Medical Sciences (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2021002666A 2018-09-07 2019-09-06 Proceso para la preparacion de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-( 3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]a nulen-2-carboxilato de metilo. MX2021002666A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18306177 2018-09-07
PCT/EP2019/073827 WO2020049153A1 (en) 2018-09-07 2019-09-06 Process for the preparation of methyl 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylate

Publications (1)

Publication Number Publication Date
MX2021002666A true MX2021002666A (es) 2021-07-16

Family

ID=63637829

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021002666A MX2021002666A (es) 2018-09-07 2019-09-06 Proceso para la preparacion de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-( 3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]a nulen-2-carboxilato de metilo.
MX2021002665A MX2021002665A (es) 2018-09-07 2019-09-06 Sales de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirroli din-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anulen-2-carboxilato de metilo y proceso de preparación de las mismas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021002665A MX2021002665A (es) 2018-09-07 2019-09-06 Sales de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirroli din-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anulen-2-carboxilato de metilo y proceso de preparación de las mismas.

Country Status (18)

Country Link
US (2) US11713296B2 (ko)
EP (2) EP3847156B1 (ko)
JP (2) JP7398436B2 (ko)
KR (2) KR20210057031A (ko)
CN (2) CN112638870A (ko)
AR (2) AR116300A1 (ko)
AU (2) AU2019335542A1 (ko)
BR (2) BR112021003061A2 (ko)
CA (2) CA3111359A1 (ko)
DK (2) DK3847156T3 (ko)
ES (2) ES2924738T3 (ko)
HU (2) HUE059527T2 (ko)
IL (2) IL281191B (ko)
MX (2) MX2021002666A (ko)
SG (2) SG11202102059YA (ko)
TW (2) TW202026280A (ko)
WO (2) WO2020049150A1 (ko)
ZA (2) ZA202101006B (ko)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3434272A1 (en) 2017-07-25 2019-01-30 Sanofi Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
ES2924738T3 (es) 2018-09-07 2022-10-10 Sanofi Sa Proceso para la preparación de 6-(2,4-diclorofenil)-5-[4-[(3S)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7H-benzo[7]anuleno-2-carboxilato de metilo y una sal del mismo
CA3160897A1 (en) 2019-12-09 2021-06-17 Sanofi Crystalline form of a 7h-benzo[7]annulene-2-carboxylic acid derivative
US20230242507A1 (en) 2020-06-28 2023-08-03 Medshine Discovery Inc. Indazole-fused cyclic compound
CA3196103A1 (en) 2020-10-19 2022-04-28 Patrick Bernardelli Substituted 6,7-dihydro-5h-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof
US20240101512A1 (en) 2020-10-19 2024-03-28 Sanofi Substituted 6,7-Dihydro-5H-Benzo[7]Annulene Compounds and Their Derivatives, Processes for Their Preparation and Therapeutic Uses Thereof
WO2023187086A1 (en) 2022-03-31 2023-10-05 Sanofi Amorphous solid form of amcenestrant
WO2023198901A1 (en) 2022-04-15 2023-10-19 Sanofi Novel substituted 4-amino-4-oxo-but-2-enyl derivatives, processes for their preparation and therapeutic uses thereof
WO2023198904A1 (en) * 2022-04-15 2023-10-19 Sanofi Substituted 6,7-dihydro-5h-benzo[7]annulene derivatives, processes for their preparation and therapeutic uses thereof
WO2023198905A1 (en) 2022-04-15 2023-10-19 Sanofi Novel substituted fluorinated vinyl-n-propyl-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof
WO2023198879A1 (en) 2022-04-15 2023-10-19 Sanofi Novel substituted fluorinated n-propyl-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof
WO2023198903A1 (en) 2022-04-15 2023-10-19 Sanofi Novel substituted fluorinated n-propyl-pyrrolidine and n‑propyl-azetidine compounds, processes for their preparation and therapeutic uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015579A1 (en) 1991-03-08 1992-09-17 Rhone-Poulenc Rorer International (Holdings) Inc. Multicyclic tertiary amine polyaromatic squalene synthetase inhibitors
DE19833786A1 (de) 1998-07-18 2000-01-20 Schering Ag Benzocycloheptene, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
ATE286893T1 (de) 2001-01-24 2005-01-15 Chiesi Farma Spa 2h-1-benzopyran-derivative, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
HUP0500573A2 (hu) 2001-08-11 2005-11-28 Bristol-Myers Squibb Pharma Company Trifenil-etilén származékok, mint szelektív ösztrogén receptor modulátorok és ezeket tartalmazó gyógyszerkészítmények
PT1501819E (pt) 2002-04-24 2010-11-11 Merck Sharp & Dohme Moduladores dos receptores de estrogéneo
CA2512000C (en) 2002-12-26 2011-08-09 Eisai Co., Ltd. Selective estrogen receptor modulator
KR101229416B1 (ko) 2004-06-25 2013-02-05 얀센 파마슈티카 엔.브이. 사차염 ccr2 길항제
CA2611712C (en) 2005-06-14 2014-05-13 Baylor University Combretastatin analogs with tubulin binding activity
US8127618B1 (en) 2007-05-18 2012-03-06 Pacesetter, Inc. Implantable micro-electromechanical system sensor
EP2048126A1 (de) 2007-10-11 2009-04-15 Bayer Schering Pharma AG Benzocycloheptanderivate als selektiv wirksame Estrogene
WO2009101634A2 (en) 2008-02-13 2009-08-20 Lupin Limited A novel process for the preparation of eszopiclone
DE102010030538A1 (de) 2010-06-25 2011-12-29 Bayer Schering Pharma Aktiengesellschaft 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
WO2012068284A2 (en) 2010-11-16 2012-05-24 Baylor University Efficient method for preparing functionalized benzosuberenes
US9540361B2 (en) 2010-12-24 2017-01-10 Merck Sharp & Dohme B.V. N-substituted azetidine derivatives
DE102011087987A1 (de) 2011-12-08 2013-06-13 Bayer Intellectual Property Gmbh 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
CN102584687A (zh) 2011-12-30 2012-07-18 北京赛林泰医药技术有限公司 作为选择性雌激素受体调节剂的乙烯衍生物
CN105658628A (zh) 2011-12-30 2016-06-08 北京赛林泰医药技术有限公司 新型芳基乙烯衍生物及其在选择性雌激素受体调节剂中的应用
PL3033086T3 (pl) 2013-08-14 2022-01-31 Novartis Ag Terapia skojarzona do leczenia nowotworów złośliwych
WO2015028409A1 (de) 2013-08-27 2015-03-05 Bayer Pharma Aktiengesellschaft 6,7-dihydro-5h-benzo[7]annulen-derivate, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
SG11201604501TA (en) 2013-12-06 2016-07-28 Hoffmann La Roche Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer
WO2016097071A1 (en) 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Estrogen receptor modulators and uses thereof
SG10202100799PA (en) 2014-12-18 2021-03-30 Hoffmann La Roche TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
IL310069A (en) 2015-04-29 2024-03-01 Radius Pharmaceuticals Inc Cancer treatment methods
CN106924210A (zh) 2015-12-29 2017-07-07 北京新领先医药科技发展有限公司 一种含有帕布昔利布的胶囊剂及其制备方法
CN108884079B (zh) 2016-02-15 2021-03-05 赛诺菲 作为雌激素受体调节剂的6,7-二氢-5h-苯并[7]轮烯衍生物
SG11201903908PA (en) 2016-11-17 2019-05-30 Sanofi Sa Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof
EP3434272A1 (en) * 2017-07-25 2019-01-30 Sanofi Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
ES2924738T3 (es) * 2018-09-07 2022-10-10 Sanofi Sa Proceso para la preparación de 6-(2,4-diclorofenil)-5-[4-[(3S)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7H-benzo[7]anuleno-2-carboxilato de metilo y una sal del mismo
JP2022507495A (ja) 2018-11-16 2022-01-18 アーキュール・インコーポレイテッド 癌治療のための医薬の組合せ
MX2021013711A (es) 2019-05-09 2021-12-10 Sanofi Sa Acido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin -3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxilico para su uso en pacientes con cancer de mama metastasico o avanzado.
KR20220046586A (ko) * 2019-07-22 2022-04-14 썬 파마 어드밴스트 리서치 컴패니 리미티드 선택적 에스트로겐 수용체 분해제
US20220389006A1 (en) * 2019-11-04 2022-12-08 Recurium Ip Holdings, Llc Salts and forms of an estrogen receptor modulator
CA3160897A1 (en) * 2019-12-09 2021-06-17 Sanofi Crystalline form of a 7h-benzo[7]annulene-2-carboxylic acid derivative

Also Published As

Publication number Publication date
TWI803692B (zh) 2023-06-01
CN112638869A (zh) 2021-04-09
HUE059362T2 (hu) 2022-11-28
CA3111466A1 (en) 2020-03-12
ES2924738T3 (es) 2022-10-10
WO2020049150A1 (en) 2020-03-12
IL281191A (en) 2021-04-29
HUE059527T2 (hu) 2022-11-28
EP3847156B1 (en) 2022-05-04
BR112021003061A2 (pt) 2021-05-11
AR116300A1 (es) 2021-04-21
IL281191B (en) 2022-07-01
US20210188772A1 (en) 2021-06-24
EP3847157B1 (en) 2022-05-18
IL281196B2 (en) 2023-02-01
AU2019335542A1 (en) 2021-04-01
JP2021536468A (ja) 2021-12-27
SG11202102059YA (en) 2021-03-30
KR20210057031A (ko) 2021-05-20
KR20210057032A (ko) 2021-05-20
DK3847156T3 (da) 2022-07-25
IL281196B (en) 2022-10-01
AR116299A1 (es) 2021-04-21
MX2021002665A (es) 2021-07-16
TW202024032A (zh) 2020-07-01
US11713296B2 (en) 2023-08-01
CN112638870A (zh) 2021-04-09
JP7398436B2 (ja) 2023-12-14
SG11202102057SA (en) 2021-03-30
AU2019336532A1 (en) 2021-04-01
JP2021536471A (ja) 2021-12-27
DK3847157T3 (da) 2022-08-08
CA3111359A1 (en) 2020-03-12
IL281196A (en) 2021-04-29
ZA202101079B (en) 2022-09-28
EP3847157A1 (en) 2021-07-14
EP3847156A1 (en) 2021-07-14
JP7413363B2 (ja) 2024-01-15
ES2923412T3 (es) 2022-09-27
ZA202101006B (en) 2022-08-31
BR112021003440A2 (pt) 2021-05-18
US20210188771A1 (en) 2021-06-24
WO2020049153A1 (en) 2020-03-12
TW202026280A (zh) 2020-07-16

Similar Documents

Publication Publication Date Title
MX2021002666A (es) Proceso para la preparacion de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-( 3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]a nulen-2-carboxilato de metilo.
MX2019004254A (es) Moleculas que tienen utilidad plaguicida, e intermediarios, composiciones, y procesos, relacionados a las mismas.
AR094588A2 (es) Proceso de obtención de un compuesto derivado de benzimidazol y composición farmacéutica
TW200720293A (en) Process for preparing latices stabilized by polyvinyl alcohol
MX346318B (es) Cristales.
MA32749B1 (fr) Composes insecticides
MX2010001415A (es) Procedimiento para sintetizar compuestos utiles para tratar hepatitis c.
TW200621722A (en) 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
EP4335439A3 (en) Compounds
MX2009006865A (es) Proceso para la preparacion de compuestos 6,6-dimetil-3-aza-bicicl o-[3.1.0]-hexano utilizando intermediario bisulfitico.
GEP20135956B (en) Chemical process
PH12019502037A1 (en) Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
WO2008110281A3 (de) 3,4-disubstituierte phenoxyphenylamidine und deren verwendung als fungizide
MX2020010418A (es) Moleculas que tienen utilidad plaguicida, composiciones y proceso para controlar plagas relacionados con estas.
NZ598579A (en) Oxytocin receptor agonists
MX2018008845A (es) Moléculas que tienen utilidad plaguicida, e intermediarios, composiciones y procesos, relacionados con ellas.
MX2009003823A (es) Nueva difenilazetidinona sustituida con acido piperazina-1-sulfonico y que tiene propiedades farmacologicas mejoradas.
IN2012DN03391A (ko)
WO2007057225A3 (en) Process for making montelukast and intermediates therefor
MX2017006136A (es) Moleculas que tienen utilidad plaguicida e intermediarios, composiciones y procedimientos relacionados con las mismas.
EP2404912A3 (en) Process and intermediates for the preparation of antitumoral dihydropyran-2-one compounds
AR064658A1 (es) Proceso para preparar duloxetina y sus compuestos relacionados, asi como tambien intermediarios utiles en la misma
MXPA05013751A (es) Procedimiento e intermediarios para la preparacion de 3-(amino)-3-ciclobutilmetil-2-hidroxi-propionamida o sus sales.
MX2021014855A (es) {6-[(2-amino-3-cloropiridin-4-il)sulfanil]-3-[(3s,4s)-4-amino-3-m etil-2 oxa-8-azaspiro[4.5]decan-8-il]-5-metilpirazin-2-il}metanol, un inhibidor de shp2.
MX2020011671A (es) Nuevo proceso para la preparacion de diamidas antranilicas.